ヒト成長ホルモンの世界市場2018-2022

◆英語タイトル:Global Human Growth Hormone Market 2018-2022
◆商品コード:IRTNTR23746
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月14日
◆ページ数:110
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、ヒト成長ホルモンの世界市場について調査・分析し、市場概要、市場環境、ヒト成長ホルモン市場規模、薬剤種類別分析、用途別(ISS、成長ホルモン欠乏、ターナー症候群、PWS、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・ヒト成長ホルモンの世界市場概要
・ヒト成長ホルモンの世界市場環境
・ヒト成長ホルモンの世界市場動向
・ヒト成長ホルモンの世界市場規模
・ヒト成長ホルモンの世界市場:業界構造分析
・ヒト成長ホルモンの世界市場:薬剤種類別
・ヒト成長ホルモンの世界市場:用途別(ISS、成長ホルモン欠乏、ターナー症候群、PWS、その他)
・ヒト成長ホルモンの世界市場:地域別市場規模・分析
・ヒト成長ホルモンの北米市場規模・予測
・ヒト成長ホルモンのヨーロッパ・中東・アフリカ市場規模・予測
・ヒト成長ホルモンのアジア太平洋市場規模・予測
・ヒト成長ホルモンの主要国分析
・ヒト成長ホルモンの世界市場:意思決定フレームワーク
・ヒト成長ホルモンの世界市場:成長要因、課題
・ヒト成長ホルモンの世界市場:競争環境
・ヒト成長ホルモンの世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、Eli Lilly、F. Hoffmann-La Roche、Novo Nordisk、and Pfizerなどです。
【レポートの概要】

About this market
Increasing incidence and prevalence of growth hormone disorders due to the growth hormone deficiency is expected to drive the human growth hormone market over the forecast period. Moreover, various indications fall under the growth hormone disorders such as turner syndrome, growth hormone deficiency, acromegaly, Noonan syndrome, gigantism, and many more. Technavio’s analysts have predicted that the human growth hormone market will register a CAGR of almost 4% by 2022.
Market Overview
Strong pipeline of human growth hormone
Many leading companies such as Novo Nordisk, Merck, and Pfizer have a strong pipeline in their portfolio for treating various growth hormone disorders. All these factors are expected to drive the global human growth hormone market during the forecast period.
Poor patient adherence
The poor patient adherence for human growth hormone due to uneasiness with growth hormone administration will impact the treatment adherence and results.
For the detailed list of factors that will drive and challenge the growth of the human growth hormone market during the 2018-2022, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Novo Nordisk and Pfizer the competitive environment is quite intense. Factors such as the strong pipeline of human growth hormone and the increasing incidence and prevalence of growth hormone disorders, will provide considerable growth opportunities to human growth hormone manufactures. Eli Lilly, F. Hoffmann-La Roche, Novo Nordisk, and Pfizer are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Human growth hormone pipeline analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY DRUG TYPE
• Segmentation by drug type
PART 09: MARKET SEGMENTATION BY APPLICATION
• Segmentation by application
• Comparison by application
• Growth hormone deficiency – Market size and forecast 2017-2022
• ISS – Market size and forecast 2017-2022
• Turner syndrome – Market size and forecast 2017-2022
• PWS – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by application
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
• Increasing incidence of growth disorders
• No impact of biosimilar entry into market
• Advanced technologies
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Eli Lilly
• F. Hoffmann-La Roche
• Novo Nordisk
• Pfizer
PART 17: APPENDIX
• List of abbreviations

Exhibit 01: Parent market
Exhibit 02: Global human growth hormone market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs under Phase III stage of development 2017-2018
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global – Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global – Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: Application – Market share 2017-2022 (%)
Exhibit 20: Comparison by application
Exhibit 21: Growth hormone deficiency – Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Growth hormone deficiency – Year-over-year growth 2018-2022 (%)
Exhibit 23: ISS– Market size and forecast 2017-2022 ($ mn)
Exhibit 24: ISS – Year-over-year growth 2018-2022 (%)
Exhibit 25: Turner syndrome – Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Turner syndrome – Year-over-year growth 2018-2022 (%)
Exhibit 27: PWS – Market size and forecast 2017-2022 ($ mn)
Exhibit 28: PWS – Year-over-year growth 2018-2022 (%)
Exhibit 29: Others – Market size and forecast 2017-2022 ($ mn)
Exhibit 30: Others – Year-over-year growth 2018-2022 (%)
Exhibit 31: Market opportunity by application
Exhibit 32: Customer landscape
Exhibit 33: Global – Market share by geography 2017-2022 (%)
Exhibit 34: Regional comparison
Exhibit 35: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 36: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in Americas
Exhibit 38: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 39: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in EMEA
Exhibit 41: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 42: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 43: Top 3 countries in APAC
Exhibit 44: Market opportunity
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Eli Lilly – Overview
Exhibit 51: Eli Lilly – Business segments
Exhibit 52: Eli Lilly – Organizational developments
Exhibit 53: Eli Lilly – Geographic focus
Exhibit 54: Eli Lilly – Segment focus
Exhibit 55: Eli Lilly – Key offerings
Exhibit 56: Eli Lilly – Key customers
Exhibit 57: F. Hoffmann-La Roche – Overview
Exhibit 58: F. Hoffmann-La Roche – Business segments
Exhibit 59: F. Hoffmann-La Roche – Organizational developments
Exhibit 60: F. Hoffmann-La Roche – Geographic focus
Exhibit 61: F. Hoffmann-La Roche – Segment focus
Exhibit 62: F. Hoffmann-La Roche – Key offerings
Exhibit 63: F. Hoffmann-La Roche – Key customers
Exhibit 64: Novo Nordisk – Overview
Exhibit 65: Novo Nordisk– Business segments
Exhibit 66: Novo Nordisk – Organizational developments
Exhibit 67: Novo Nordisk – Geographic focus
Exhibit 68: Novo Nordisk – Segment focus
Exhibit 69: Novo Nordisk– Key offerings
Exhibit 70: Pfizer – Overview
Exhibit 71: Pfizer – Business segments
Exhibit 72: Pfizer – Organizational developments
Exhibit 73: Pfizer – Geographic focus
Exhibit 74: Pfizer – Segment focus
Exhibit 75: Pfizer – Key offerings
Exhibit 76: Pfizer – Key customers



【掲載企業】

Eli Lilly、F. Hoffmann-La Roche、Novo Nordisk、and Pfizer

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ヒト成長ホルモンの世界市場2018-2022]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆